BN171: Newsflash October 2025! More than 800 people already registered! Still 4 weeks to wait for an amazing meeting fully dedicated to Endourology! So join the Endo-Family and come to the Eternal city. « Because we all LOVE EndoUrology »♥️♥️♥️

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert

⚡️ Cost-effectiveness of treatments for BCG-unresponsive CIS - analysis from our multicenter IBCG team. Five strategies modeled: 🔹Radical cystectomy (RC) 🔹Pembrolizumab 🔹Nadofaragene firadenovec 🔹Nogapendekin (NAI-BCG) 🔹Gemcitabine + Docetaxel ➡️Comprehensive

@tompowles1 @PGrivasMDPhD @SimaPorten @paolo_gontero @MariaJRibal @MaxKates @mouwlab @AndreaNecchi (5/5) 🔬 Surveillance & Trials • Cystoscopy @ 3 mo → q6 mo × 2 yrs → annually if no recurrence. • Routine cytology / enhanced cystoscopy not needed for most. • Trials should use risk-stratified controls, 10% effect size for 2-yr RFS, and include patient-reported QoL

🆕 in European Urology Exploratory analysis of IMvigor010 shows: 🔹 ctDNA is a strong prognostic marker after NAC + cystectomy 🔹 No clear adjuvant atezo benefit in ctDNA– pts Full text 👉 https://t.co/WoMLDjUscv #BladderCancer #ctDNA #Immunotherapy

✒️ Platinum Opinion Editorial in European Urology @UroDocAsh, @josedsh, @Pietro9609 et al. challenge the guideline call for upfront RC in very high-risk NMIBC: 🔹 Adequate BCG → favorable 5-yr outcomes 🔹 RC & BCG show similar survival in real-world data 🔹 Risk of overtreatment

📖 European Urology Editor’s Choice MacLennan et al. update the evidence on lower pole renal stones: 🔹 PCNL = highest SFR 🔹 FURS > ESWL (especially >10 mm) 🔹 ESWL = least invasive, fewer complications but more retreatments 🔹 Evidence certainty still moderate; QoL & cost data

On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG - unresponsive NMIBC with CIS with or without papillary tumors. Also known as TAR-200: this gemcitabine intravesical system is

JUST IN: Tar200 now @US_FDA approved based on SunRise-1 phase 2 trial in BCG unresponsive NMIBC. -Intravesical form of Gemcitabine - CR: 82.4%/grade ≥3 AE 12.9% - DFS 70.2% at 12m - 51% of CRs with DOR ≥ 12 months.

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4

🚨New in @BJUIjournal Study on IR-NMIBC: - 0 IBCG RF → induction only sufficient - 1–2 RF → 35% ↓ recurrence w/ maintenance - ≥3 RF → 52% ↓ recurrence w/ maintenance IBCG stratification may guide risk-adapted therapy Full text👉 https://t.co/ggcLtDZEqd #BladderCancer

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. https://t.co/dPqlvr2rnV

Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer https://t.co/8Yox2puKEg Article highlights that while #ProstateCancer (PCa) is the most common cancer among men in high-income countries, most men diagnosed with nonmetastatic PCa—especially

@ASCOPost @JCO_ASCO @siadaneshmand This represents a real step forward in patient-centered bladder preservation and checks all the boxes patients ask for TAR-200: a small drug-eluting device placed in the bladder at ✅manageable intervals (3 - 12 weeks) ✅82% complete responses, with majority disease free at

We’re all excited to see the data and hopeful , but there’s real concern about starting with EV/P upfront and having no better or equivalent option if recurrence happens later ❗️Yes, fewer recurrences mean less need down the line but it’s sometimes not that straightforward

Multicenter European trial investigates gem/doce for #NMIBC. @Pietro9609 @SanRaffaeleMI joins @zklaassen_md @GACancerCenter sharing European real-world data on gem/doce for BCG-unresponsive NMIBC: 79% HG disease-free survival and 95% 1-yr PFS with excellent tolerability. A

🔬 New in @EUEuropeanUrol: The PUrE RCT 1 compares FURS vs. ESWL for lower pole kidney stones ≤10 mm. 🧑⚕️💰 A landmark trial on both clinical and cost effectiveness. #UroTwitter #Urolithiasis 1/ 📈 Findings from 461 randomized patients (48 UK centers): ✔️ Stone-free: FURS 72%

🌍📈🧬 #Epidemiology of #RenalCancer: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors https://t.co/YKFXuvZzP9 Up-to -date facts and figures together with future projections at @EUplatinum

Our SEER-based study shows that pts with cN+ M0 bladder cancer who received chemotherapy + radical cystectomy had better CSS and OS compared to those who had chemoradiation. The 5-yr OS was only 25%. https://t.co/sjsZOlStnf @Pietro9609 @UroMoschini @BenjaminPradere @SBoorjian

In men with nonmetastatic PCa, 30-yr mortality from PCa was lower than mortality from other causes, even among those with very high-risk disease. “Our data support adherence to guideline recommendations for treatment of prostate cancer,” says @Pietro9609. https://t.co/1n2mJDC2gN